Palisade Bio, Inc. (PALI) has a consensus analyst rating of Buy, based on 3 analysts covering the stock. Of those, 3 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for PALI is $1.50, representing a -27.2% downside from the current price of $2.06. Price targets range from a low of $1.50 to a high of $1.50.
